Viracta Therapeutics Inc. (VIRX)

Name: Viracta Therapeutics Inc. (VIRX) Share Price Today, Stock Analysis, Annual Report | Value Research
Brand: Viracta Therapeutics Inc. (VIRX)

Stock Card

$0.01

$-0.03 (-72.16%)

As on 30-Dec-2025 16:00EDT

Market cap

$0 Mln

Revenue (TTM)

$1 Mln

P/E Ratio

P/B Ratio

Div. Yield

0 %

Viracta Therapeutics (VIRX) Share Price

Compare

High: Low: Return:

Price P/E Ratio P/B Ratio

Stock Range

Today’s Range

Low: 0.01 High: 0.01

52 Week Range

Low: 0.01 High: 0.24

Liquidity

Low Moderate High

Fundamentals

Net Profit (TTM)

$0 Mln
ROE

-3.7 %
ROCE

-- %
Industry P/E

--
EV/EBITDA

-0.5
Debt to Equity

0
Book Value

$--
EPS

$-1.1
Face value

--
Shares outstanding

39,744,200

10 Years Aggregate

CFO

$-311.86 Mln

EBITDA

$-241.48 Mln

Net Profit

$-533.13 Mln

Company	YTD	1 Month	3 Months	1 Year	3 Years	5 Years	10 Years
Viracta Therapeutics (VIRX)	-93.9	--	--	-93.9	-80.2	-72.7	-62.9
BSE Sensex^*	-9.1	-1.5	2.9	-3.6	5.9	6.0	10.5
S&P Small-Cap 600^#	-5.8	-5.3	-13.7	-6.3	5.3	3.0	5.5

As on 30-Dec-2025 | *As on 01-Sep-2026 | #As on 26-Oct-2023

Company	2024	2023	2022	2021	2020	2019	2018
Viracta Therapeutics (VIRX)	-71.5	-61.0	-60.0	83.4	-41.5	-19.0	-88.5
S&P Small-Cap 600	7.0	13.9	-17.4	25.3	9.6	20.9	-9.7
BSE Sensex	8.1	18.7	4.4	22.0	15.8	14.4	5.9

Essential Checks

View Details

Is there a threat to the company's solvency?

Can creative accounting be detected through the financial numbers?

How did the company perform in the last one year?

Financials

View Details

Key Ratios

View Details

Shareholding Pattern

View Details

About Viracta Therapeutics (VIRX)

Viracta Therapeutics, Inc., a clinical-stage precision oncology company, focuses on the treatment and prevention of virus-associated cancers that impact patients worldwide. The company's lead product candidate is Nana-val, an all-oral combination... therapy of its proprietary investigational drug, nanatinostat, and the antiviral agent valganciclovir. It's Nana-val is in various ongoing clinical trials, including NAVAL-1, an open-label Phase 2 basket trial for the treatment of multiple subtypes of relapsed/refractory Epstein-Barr virus-positive (EBV+) lymphoma, as well as an open-label Phase 1b/2 trial for the treatment of EBV+ recurrent or metastatic nasopharyngeal carcinoma and other EBV+ solid tumors. The company's product pipeline also includes vecabrutinib, a clinical-stage product candidate; and VRx-510, a preclinical product candidate. The company is headquartered in Cardiff, California. Read more

CEO, President & Director

Mr. Mark Andrew Rothera
CEO, President & Director

Mr. Mark Andrew Rothera
Headquarters

Cardiff, CA
Website

https://www.viracta.com

FAQs for Viracta Therapeutics (VIRX)

What is the current share price of Viracta Therapeutics Inc (VIRX) Today?

The share price of Viracta Therapeutics Inc (VIRX) is $0.01 (NASDAQ) as of 30-Dec-2025 16:00 EDT. Viracta Therapeutics Inc (VIRX) has given a return of -80.19% in the last 3 years.

What is the current PB & PE ratio of Viracta Therapeutics Inc (VIRX)?

Since, TTM earnings of Viracta Therapeutics Inc (VIRX) is negative, P/E ratio is not available.
The P/B ratio of Viracta Therapeutics Inc (VIRX) is 3.00 times as on 30-Dec-2025, a 42 discount to its peers’ median range of 5.18 times.

PE & PB ratio at the end of financial year.

Year	P/E Ratio	P/B Ratio
2023	-0.43	1.21
2022	-1.12	0.92
2021	-0.67	1.45
2020	-3.85	-1.60
2019	-0.16	0.14

What is the 52 Week High and Low of Viracta Therapeutics Inc (VIRX)?

The 52-week high and low of Viracta Therapeutics Inc (VIRX) are Rs 0.24 and Rs 0.01 as of 01-Sep-2026.

What is the market cap of Viracta Therapeutics Inc (VIRX)?

Viracta Therapeutics Inc (VIRX) has a market capitalisation of $ 0 Mln as on 30-Dec-2025. As per SEBI classification, it is a Small Cap company.

Should I invest in Viracta Therapeutics Inc (VIRX)?

Before investing in Viracta Therapeutics Inc (VIRX), assess your goals, risk tolerance, and if the company aligns with your long-term plan. Carefully review its business model, financials, and valuation. Avoid making decisions based on tips or short-term trends.

For guidance, explore our expert-curated portfolios and Stock recommendations with Value Research Stock Advisor.

Want to explore on your own? Click here to see how this stock scores on quality, growth, valuation, and momentum.